Willingness to Pay for a Quality-adjusted Life Year

Medical Decision Making - Tập 20 Số 3 - Trang 332-342 - 2000
Richard A. Hirth1, Michael E. Chernew2, Edward L. Miller2, A. Mark Fendrick3, William G. Weissert2
1Health Management and Policy
2UNIVERSITY OF MICHIGAN
3Internal Medicine - General Medicine

Tóm tắt

Cost-benefit analysis (CBA) provides a clear decision rule: undertake an intervention if the monetary value of its benefits exceed its costs. However, due to a reluctance to characterize health benefits in monetary terms, users of cost-utility and cost-effectiveness analyses must rely on arbitrary standards (e.g., < $50,000 per QALY) to deem a program "cost-effective." Moreover, there is no consensus regarding the appropriate dollar value per QALY gained upon which to base resource allocation decisions. To address this, the authors determined the value of a QALY as implied by the value-of-life literature and compared this value with arbitrary thresholds for cost-effectiveness that have come into common use. A literature search identified 42 estimates of the value of life that were appropriate for inclusion. These estimates were classified by method: human capital (HK), contingent valuation (CV), revealed preference/job risk (RP-JR) and revealed preference/non-occupational safety (RP-S), and by U.S. or non-U.S. origin. After converting these value-of-life estimates to 1997 U.S. dollars, the life expectancy of the study population, age-specific QALY weights, and a 3% real discount rate were used to calculate the implied value of a QALY. An ordinary least-squares regression of the value of a QALY on study type and national origin explained 28.4% of the variance across studies. Most of the explained variance was attributable to study type; national origin did not significantly affect the values. Median values by study type were $24,777 (HK estimates), $93,402 (RP-S estimates), $161,305 (CV estimates), and $428,286 (RP-JR estimates). With the exception of HK, these far exceed the "rules of thumb" that are frequently used to determine whether an intervention produces an acceptable increase in health benefits in exchange for incremental expenditures. Key words: cost-effectiveness analysis; cost-utility analysis; quality-adjusted life years; value of life. (Med Decis Making 2000;20:332-342)

Từ khóa


Tài liệu tham khảo

10.1177/0272989X9901900403

10.1177/0272989X9901900404

10.1016/0167-6296(87)90009-9

Gafni A, 1993, Can Med Assoc J, 148, 913

10.1016/0277-9536(94)E0109-6

10.1016/S0167-6296(99)00014-4

10.1002/(SICI)1099-1050(199802)7:1<9::AID-HEC304>3.0.CO;2-H

10.1002/(SICI)1099-1050(199802)7:1<21::AID-HEC306>3.0.CO;2-9

10.1002/(SICI)1099-1050(199802)7:1<1::AID-HEC327>3.0.CO;2-U

10.1007/BF00662136

10.1001/jama.1996.03530350040032

10.1111/j.1539-6924.1995.tb00330.x

10.7326/0003-4819-126-5-199703010-00001

10.7326/0003-4819-127-11-199712010-00001

Laupacis A, 1992, Can Med Assoc J., 146, 473

Weinstein MC, 1995, From cost-effectiveness ratios to resource allocation: where to draw the line?

10.1056/NEJM199505253322106

U.S. Renal Data System., 1998, USRDS 1998 Annual Data Report

10.1016/0895-4356(92)90099-9

10.1001/jama.1996.03530380065033

10.1177/0272989X9901900401

10.1177/0272989X9901900402

10.1177/0272989X9901900405

10.4159/harvard.9780674186217

10.2307/3323835

10.1086/261149

10.2307/2109748

10.1086/260777

Cooper BS, 1976, Social Security Bulletin, 39, 21

Desaigues B, Rabl A. Reference values for human life an economic analysis of a continguent valuation in France In. Schwab Christe NG, Soguel NC. (eds). Contingent Valuation, Transport Safety and the Value of Life Boston, MA: Kluwer Academic Publishers , 1995; 85-112.

10.1111/j.1465-7295.1985.tb01765.x

10.1086/467326

10.1007/BF00141954

10.1007/BF00056167

10.1111/j.1467-9957.1975.tb01231.x

10.2105/AJPH.70.12.1249

10.2307/2109354

10.1016/0047-2727(84)90044-6

10.2307/2233468

Kidholm K. Assessing the value of traffic safety using the contingent valuation technique: the Danish survey In: Schwab Christe NG, Soguel NC (eds). Contingent Valuation, Transport Safety and the Value of Life. Boston, MA: Kluwer Academic Publishers, 1995:45-61

10.2105/AJPH.72.6.555

10.1007/BF01207553

10.1016/0167-6296(87)90012-9

10.1006/jeem.1995.1006

10.1086/261094

10.2307/135867

Max W, 1990, Inquiry, 27, 332

10.1007/BF00057571

10.2307/135678

10.2307/3323726

10.1111/j.1465-7295.1988.tb01502.x

10.1016/0095-0696(90)90037-Y

10.1007/BF00353348

10.2307/145507

10.1016/0095-0696(81)90058-9

10.2105/AJPH.57.3.424

10.2105/AJPH.57.11.1954

10.1007/BF00056139

10.1007/BF01073403

Viscusi WK., 1978, Public Policy, 26, 359

10.1016/0047-2727(89)90061-3

National Center for Health Statistics., 1997, Vital Statistics of the United States, 1993, preprint of Vol. II, mortality, part A sec 6 life tables

Gold MR, 1996, Cost-Effectiveness in Health and Medicine, 10.1093/oso/9780195108248.001.0001

10.1177/0272989X9301300202

Shepard DS, Zeckhauser RJ. Life-cycle consumption and willingness to pay for increased survival In Jones-Lee, MW (ed). The Value of Life and Safety. Geneva, Switzerland North-Holland Publishing Company, 1982;95-141

1993, Valuation Federal Register, 58, 4602

10.1257/jep.8.4.45

10.2307/1244548

10.1093/jnci/89.14.1015

10.1056/NEJM199704173361612